• Network Medicine Reveals Apigenin’s Neuroprotective Mechanis

  2026-07-06

  This study pioneers a network medicine framework to systematically identify flavonoid compounds with therapeutic potential for Alzheimer’s disease. Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) is highlighted for its robust neuroprotective effects, mediated through apoptosis and neuroinflammation modulation, offering promising avenues for translational research.

• GSK126 EZH2 Inhibitor: Precision Epigenetic Targeting in Can

  2026-07-06

  Discover how the GSK126 EZH2 inhibitor empowers advanced cancer epigenetics research by enabling precise, mechanistically informed targeting of PRC2-regulated gene networks. This article offers in-depth insights into assay design and translational oncology applications.

• Applied Workflows with the Alcian Blue & Nuclear Fast Red St

  2026-07-05

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 offers streamlined, high-contrast detection of mucopolysaccharides and chondrogenic differentiation, uniquely optimized for small tissue biopsies and stem cell assays. Robust performance, simplified protocols, and effective troubleshooting set this APExBIO solution apart for advanced histological research.

• Co-Targeting BRD4 and RAC1 Disrupts c-MYC/G9a Axis in Breast

  2026-07-04

  A recent study demonstrates that simultaneous inhibition of BRD4 and RAC1 disrupts the c-MYC/G9a/FTH1 axis, suppressing growth, stemness, and tumorigenesis across breast cancer subtypes. These results highlight the mechanistic importance of epigenetic regulation and open new avenues for targeted therapy research.

• EPZ-6438 (SKU A8221): Reliable EZH2 Inhibition for Lab Assay

  2026-07-03

  This article delivers an evidence-based, scenario-driven exploration of EPZ-6438 (SKU A8221) as a selective EZH2 inhibitor for cell viability, proliferation, and epigenetic cancer research workflows. Drawing on peer-reviewed data and real-world lab challenges, it clarifies how EPZ-6438 supports reproducible results, protocol optimization, and robust interpretation, guiding biomedical researchers toward validated best practices.

• Triacetin (SKU BA1710): Enhancing Cell Assay Reliability

  2026-07-03

  Triacetin (SKU BA1710) delivers reproducible, high-quality results in cell viability, proliferation, and cytotoxicity assays. This article addresses real-world laboratory challenges and demonstrates how Triacetin's mechanistic specificity, chemical stability, and proven safety profile make it the reagent of choice for demanding biomedical workflows.

• Decitabine (5-Aza-2'-deoxycytidine): Beyond Demethylation in

  2026-07-02

  Explore how Decitabine (5-Aza-2'-deoxycytidine) uniquely bridges cancer epigenetics and immune tolerance, offering new strategies for tumor suppressor gene reactivation and immunomodulation. This in-depth review highlights mechanistic details and fresh assay insights for researchers.

• Trichostatin A (TSA): Applied HDAC Inhibition in Cancer Rese

  2026-07-02

  Trichostatin A (TSA) empowers researchers to dissect epigenetic mechanisms underlying cancer cell fate, offering workflow-ready protocols for robust, reproducible modulation of cell proliferation and differentiation. By leveraging TSA’s potent and reversible HDAC inhibition, scientists can interrogate novel regulatory axes—such as ferroptosis sensitivity in colorectal cancer—while overcoming common experimental bottlenecks.

• Epigenetic Regulation of MIR9 in ALL: Pathway Deregulation a

  2026-07-01

  This study demonstrates that hypermethylation-driven silencing of the MIR9 family in acute lymphoblastic leukaemia (ALL) leads to oncogenic activation of FGFR1 and CDK6. The findings identify MIR9 methylation as a robust prognostic marker and suggest new therapeutic targets within epigenetically deregulated pathways.

• BRD4770: G9a Histone Methyltransferase Inhibitor in Cancer R

  2026-07-01

  BRD4770 is a precise G9a histone methyltransferase inhibitor that empowers researchers to dissect epigenetic regulation and cellular senescence in cancer models. Its robust activity in modulating histone H3K9 methylation and ability to induce senescence in difficult-to-treat tumor cell lines set it apart as a leading research tool for advanced cancer biology.

• Propranolol’s Modulation of Metabolic Pathways After Severe

  2026-06-30

  This article examines a phase II randomized controlled trial showing that propranolol profoundly alters metabolic and lipidomic profiles in severely burned patients, leading to improved clinical outcomes. The study’s untargeted metabolomics approach reveals specific shifts in energy and nucleotide metabolism, offering mechanistic insights into how beta-blockade mitigates burn-induced hypermetabolic stress.

• GSK J4 HCl: Precision JMJD3 Inhibition for Decidual Epigenet

  2026-06-30

  Dive deep into how GSK J4 HCl, a potent JMJD3 inhibitor, is advancing decidual epigenetic research and immune modulation. Discover unique insights on assay design and translational relevance, building on pivotal chromatin regulation breakthroughs.

• JNJ-26481585 (Quisinostat): Redefining TRIM21-Targeted Epige

  2026-06-29

  Explore how JNJ-26481585 (Quisinostat) advances cancer research by targeting TRIM21-mediated resistance through epigenetic modulation. Uncover its unique mechanism, practical assay advantages, and emerging applications in overcoming therapeutic barriers.

• Dual BRD4/RAC1 Inhibition Disrupts c-MYC–G9a Axis in Breast

  2026-06-29

  The referenced study reveals that co-targeting BET bromodomain BRD4 and RAC1 disrupts the oncogenic c-MYC–G9a–FTH1 regulatory axis and downregulates HDAC1, leading to reduced growth, stemness, and tumorigenesis in diverse breast cancer subtypes. These findings highlight the therapeutic promise of epigenetic modulation, suggesting new avenues for targeted intervention in heterogeneous breast cancers.

• JNJ-26481585 (Quisinostat): Targeting TRIM21 for Epigenetic

  2026-06-28

  Explore how JNJ-26481585 (Quisinostat) uniquely suppresses TRIM21 to overcome tumor proliferation and drug resistance. This in-depth analysis reveals advanced epigenetic insights and practical assay considerations for cancer researchers.

16765 records 1/1118 page Next 12345 下5页 Last page